• Qletli, Biosimilar to Humira, Now Available in China to Treat Certain Autoimmune Diseases
  • As a New Year Begins, I’m Seeking the Silver Lining with AS
  • Levels of DNASE1L3 Protein Are Potential Biomarker of Ankylosing Spondylitis, Study Suggests
  • Mabpharm Seeks Approval of Infliximab Biobetter in China
  • Reflecting on My Past Year with Ankylosing Spondylitis
  • nr-axSpA Patients Less Likely to be Treated With Biologics Than Those With Ankylosing Spondylitis, US Survey Shows
  • First Patient Dosed in Phase 3 Trial in China Testing Enbrel Biosimilar SCB-808
  • Inflammation May Lead to Underestimating Efficacy of TNF Inhibitors, Study Suggests
  • AS Patients on Taltz Treatment Experienced Less Fatigue and Pain, and Better Sleep Over 1 Year, Phase 3 Trials Show
  • Simponi Aria Leads to Sustained Improvements in Quality of Life for Adults with Active AS, Phase 3 Trial Shows
  • FDA Approves Avsola, Remicade Biosimilar, to Treat Active Ankylosing Spondylitis
  • HHS Secretary Alex Azar Touts White House Efforts to Cure Rare Diseases